Industry news that matters to you.  Learn more

Proteome Sciences, Moffitt Cancer Center Collaborate on Clinical Mass Spectrometry Assays for Assessment of Cancer Patients

Reading time: 1 – 2 minutes

Proteome Sciences plc (“Proteome”) a global leader in applied proteomics has entered into a collaboration agreement with Moffitt Cancer Center (“Moffitt”). Under the agreement, Proteome will support research to develop mass spectrometry assays measuring certain key signalling and repair pathway proteins that can be adapted for tumour biopsy analysis in the clinic.

The Principal Investigator at Moffitt, Dr. John Koomen, commented:
“With this technical collaboration and support from Proteome Sciences we can extend the group’s activities to incorporate a large number of key proteins and post-translational modifications to rapidly translate laboratory tests into the direct management of cancer patients. We believe that knowledge of the molecular switches operating within each individual tumour will allow better selection and monitoring of treatment efficacy.”

Dr. Ian Pike, COO of Proteome Sciences added:
“There has been tremendous progress in the ability of mass spectrometers to selectively measure subtle changes in the proteins involved in cellular signalling and repair. New methods capable of simultaneously measuring these changes across several pathways are urgently needed to deliver better outcomes in all cancers. We identified the expertise of the Koomen lab as being highly complementary to our own focus of profiling post-translational modifications in major human disease. We are delighted to be working with John and look forward to launching a number of new MS assays arising from this collaboration.”

Source: Proteome Sciences